[1] |
Amagai M, Tanikawa A, Shimizu T, et al. Japanese guidelines for the management of pemphigus[J]. J Dermatol, 2014, 41(6): 471⁃486. DOI: 10.1111/1346⁃8138.12486.
|
[2] |
Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus[J]. J Am Acad Dermatol, 2008, 58(6): 1043⁃1046. DOI: 10.1016/j.jaad.2008.01.012.
|
[3] |
冯素英, 周武庆, 张洁尘, 等. 天疱疮患者桥粒芯糖蛋白抗体水平和疾病活动度关系及变化规律分析[J]. 中华皮肤科杂志, 2014, 47(7): 461⁃464. DOI: 10.3760/cma.j.issn.0412⁃4030. 2014.07.003.
|
|
Feng SY, Zhou WQ, Zhang JC, et al. Fluctuations in anti⁃desmoglein antibody levels and their relationship with disease activity in patients with pemphigus[J]. Chin J Dermatol, 2014, 47(7): 461⁃464. DOI:10.3760/cma.j.issn.0412⁃4030.2014.07.003.
|
[4] |
Gregoriou S, Efthymiou O, Stefanaki C, et al. Management of pemphigus vulgaris: challenges and solutions[J]. Clin Cosmet Investig Dermatol, 2015, 8: 521⁃527. DOI: 10.2147/CCID.S75908.
|
[5] |
Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment--guided by the European Derma⁃tology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)[J]. J Eur Acad Dermatol Venereol, 2015, 29(3): 405⁃414. DOI: 10.1111/jdv.12772.
|
[6] |
Wang M, Gao Y, Peng Y, et al. Yearly reduction of glucocorticoid dose by 50 as tapering schedule achieves complete remission for 124 pemphigus vulgaris patients[J]. J Dermatol, 2016, 43(3): 325⁃328. DOI: 10.1111/1346⁃8138.13071.
|
[7] |
渠涛, 王宝玺. 107例天疱疮回顾性研究[J]. 临床皮肤科杂志, 2002, 31(12): 756⁃759.
|
|
Qu T, Wang BX. A retrospective study of 107 cases of pemphigus[J]. J Clin Dermatol, 2002, 31(12): 756⁃759.
|
[8] |
Atzmony L, Hodak E, Leshem YA, et al. The role of adjuvant therapy in pemphigus: a systematic review and meta⁃analysis[J]. J Am Acad Dermatol, 2015, 73(2): 264⁃271. DOI: 10.1016/j.jaad.2015.04.038.
|
[9] |
Ioannides D, Apalla Z, Lazaridou E, et al. Evaluation of mycophenolate mofetil as a steroid⁃sparing agent in pemphigus: a randomized, prospective study[J]. J Eur Acad Dermatol Venereol, 2012, 26(7): 855⁃860. DOI: 10.1111/j.1468⁃3083.2011. 04170.x.
|
[10] |
Gregoriou S, Giatrakou S, Theodoropoulos K, et al. Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial[J]. Dermatology, 2014, 228(2): 158⁃165. DOI: 10.1159/000357031.
|
[11] |
Hall RP, Fairley J, Woodley D, et al. A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone[J]. Br J Dermatol, 2015, 172(3): 760⁃768. DOI: 10.1111/bjd.13350.
|
[12] |
Schmidt E, Zillikens D. Immunoadsorption in dermatology[J]. Arch Dermatol Res, 2010, 302(4): 241⁃253. DOI: 10.1007/s00403⁃009⁃1024⁃9.
|